The use of 17-hydroxy progesterone in women with arrested preterm labor: A randomized clinical trial

Background: The use of 17-alpha-hydroxyprogesterone caproate (17P) has been shown to reduce preterm delivery in women who have had a prior preterm birth. The role of 17P in women with arrested preterm labor is less certain. Aims: To compare the preterm birth rate and neonatal outcome in women with arrested preterm labor randomized to receive 17P or placebo. Materials and methods: Women with arrested preterm labor were randomized to weekly injections of either 17P (250mg) or placebo. Maternal and neonatal outcome were evaluated. Results: Forty-five singleton pregnancies were randomized after successful tocolysis; 22 received 17P while 23 got placebo. Gestational age at delivery (p=0.067) and the interval from treatment to delivery (p=0.233) were not affected by 17P. Significantly less women in the 17P group delivered at <34 weeks (14 versus 21, p=0.035). There was also a significant reduction in the risk of neonatal sepsis (p=0.047) and gr III/IV intraventricular hemorrhage (IVH) (p=0.022) in the 17P group. Conclusion: In this study, 17P did not delay the interval to delivery after successful preterm labor, but births <34 weeks as well as neonatal sepsis and IVH were reduced by 17P treatment.